Population: Infants (<1 year)

Calomfirescu-Avramescu

Romania
|
2022-2024
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Palivizumab

FIDO

United Kingdom Ireland
|
2022-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Perramon-Malavez

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Costantino

Italy
|
2022-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Ocana de Sentuary

France
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Ezpeleta

Spain
|
2023-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Oursyn

France
|
2021-2024
  • General population
  • Infants (<1 year)
  • Outpatient clinic
  • Respiratory syncytial virus

Chitgupi

Colombia Finland Ghana Honduras India Spain Thailand United States
|
2023-2024
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Primary care
  • Respiratory syncytial virus

TwinSeVeRS

France
|
2021-2022
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus

IRIS

Germany
|
2013-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Respiratory syncytial virus
  • Blood sample
  • Nasopharyngeal swab
  • Nasal lining fluid sample

PAPI Study

Germany
|
2021
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Human metapneumovirus